SNSS—(-42%)—drops Vecabrutinib (BTK) program: https://www.globenewswire.com/news-release/2020/06/23/2051898/0/en/Sunesis-Pharmaceuticals-Announces-Clinical-Update-on-Vecabrutinib-Program.html